| Hazard Information | Back Directory | [Uses]
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1]. | [in vivo]
Zuberitamab (0.1?mg/kg, intravenous injection, on day 0 and 10, 2 weeks) alone has no or minimal effect on tumor growth, when combined with BR105 results in significant inhibition of tumor growth with good anti-tumor efficacy in IRPα-humanized B-NDG mice tumor xenograft model[1].
| [References]
[1] Zhen-Hua Wu, et al. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint. J Immunother Cancer. 2022 Mar;10(3):e004054. DOI:10.1136/jitc-2021-004054 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|